In March, 2016, Teva Pharmaceuticals' Cinqair (reslizumab) was approved as an add-on maintenance treatment of severe asthma in adults not well-controlled on their current asthma medications. Cinqair reduces eosinophils, a type of white blood cell that contributes to asthma development. It is classified as an interleukin 5 antagonist monoclonal antibody (IgG4 kappa). Cinqair is given once every four weeks by injection in your doctor's office. Common side effects included anaphylaxis, cancer, and muscle pain. Nucala
Nucala (mepolizumab) is GlaxoSmithkline's IL-5 antagonist FDA-approved in November 2015 for the add-on maintenance treatment of severe eosinophilic asthma. Nucala blocks interleukin-5 and reduces inflammatory-producing white blood cell accumulation in the lungs. Like Cinqair, Nucala is given by injection every 4 weeks. Common side effects may include headache, injection site reactions, back pain, and weakness.